These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 32720870

  • 1. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, Weller M, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M.
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P, Radbruch A, Burth S, Wick A, Heiland S, Schlemmer HP, Wick W, Bendszus M, Bonekamp D.
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY.
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [No Abstract] [Full Text] [Related]

  • 6. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, Von Deimling A, Van Den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P.
    Neuro Oncol; 2020 Nov 26; 22(11):1667-1676. PubMed ID: 32393964
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A.
    Clin Transl Oncol; 2017 Jan 26; 19(1):51-57. PubMed ID: 27026567
    [Abstract] [Full Text] [Related]

  • 11. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ.
    Eur J Nucl Med Mol Imaging; 2018 Dec 26; 45(13):2377-2386. PubMed ID: 29982845
    [Abstract] [Full Text] [Related]

  • 12. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A.
    Neuroradiol J; 2019 Aug 26; 32(4):241-249. PubMed ID: 31066622
    [Abstract] [Full Text] [Related]

  • 13. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS.
    J Neurooncol; 2018 Apr 26; 137(2):439-446. PubMed ID: 29330749
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
    Bonekamp D, Mouridsen K, Radbruch A, Kurz FT, Eidel O, Wick A, Schlemmer HP, Wick W, Bendszus M, Østergaard L, Kickingereder P.
    J Cereb Blood Flow Metab; 2017 Feb 26; 37(2):485-494. PubMed ID: 26861817
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
    Nowosielski M, Gorlia T, Bromberg JEC, Sahm F, Harting I, Kickingereder P, Brandes AA, Taphoorn MJB, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Weller M, Fabbro M, Le Rhun E, Platten M, Golfinopoulos V, van den Bent MJ, Bendszus M, Wick W.
    Neurology; 2019 Jun 11; 92(24):e2754-e2763. PubMed ID: 31076534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.